Abstract
The Court's ruling in the case Merck KGaA v. Integra Lifesciences I (No. 03-1327) holds that the Federal Circuit Court of Appeals interpreted the "safe harbor" clause of the Patent Act too narrowly in June 2003 when it rejected Merck KgaA's challenge that its activities were exempt from claims of patent infringement under that statute.